Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized with Heart Failure

In this study, we aimed to: (1) determine eligibility for the PIONEER-HF trial among patients in a contemporary registry population with ADHF and HF with reduced ejection fraction ( ”all HFrEF”), (2) determine eligibility for sacubitril/valsartan using criteria most relevant to daily clinical practice (“actionable” cohort), and (3) compare long-term outcomes between the all HFrEF, PIONEER-HF trial eligible, and actionable cohorts using linked Medicare claims data.

Source: Journal of Cardiac Failure - July 31, 2019 Category: Cardiology Authors: Sabina Sayeed, Marat Fudim, Haolin Xu, Roland Matsouaka, Paul A. Heidenreich, Clyde W. Yancy, Gregg C. Fonarow, Eric J. Velazquez, Adrian F. Hernandez, Adam D. DeVore Tags: 419 Source Type: research